Current Status Of The Development Programs Of New Indications And Formulations For Aricept(R) For Enhancing Patient Value
Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") and Eisai Corporation of North America (Headquarters: Woodcliff Lake, NJ, Chairman and CEO Hajime Shimizu) are currently focusing on three clinical development programs for the company"s major product Aricept(R) (donepezil hydrochloride tablets) to further contribute to patients with Alzheimer"s disease. As progress in those programs has been made, Eisai announces the status as follows:
Sexual Health
Pages: 1 [2]
Boehringer Ingelheim To Present New Phase II Clinical Data On Two Lead Oncology Compounds At ASCO 2009
care (BSC) versus placebo plus BSC in patients with NSCLC failing 1-2 lines of chemotherapy (CT) and erlotinib or gefitinib (LUX-Lung1): a preliminary report. General Poster Session: Lung Cancer - Metastatic." Saturday 30 May 2009, Session Time: 2:00PM - 6:00PM. # 8062 6. Lynch, T. J. et al. "Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib." N. Engl. J. Med. 350, 2129-2139 (2004). 7. Paez, J. G. et al. "EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy." Science 304, 1497-1500 (2004). 8. Pao, W. et al. "EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib." Proc. Natl Acad. Sci. USA 101, 13306-13311 (2004). 9. Riely G. J. et al. "Clinical Course of Patients with Non -Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib." Clin. Cancer Res, 12, 839-844(2006). 10. Balak, M. N. et al. "Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors." Clin. Cancer Res. 12, 6494-6500 (2006). 11. Ledermann, J. A. "A randomised Phase II placebo-controlled trial using maintenance therapy to evaluate the vascular targeting agent BIBF 1120 followign treatment of relapsed ovarian cancer (OC)." Oral presentation, Clinical Science Symposium. Monday, 1 June 2009, Session Time 9:45AM - 11:15AM. # 5501 12. Hilberg F. et al. "BIBF1120 a novel, small molecule triple angiokinase inhibitor: profiling as a clinical candidate for cancer therapy." European Journal of Cancer Supplements. 2004; 2:50. 13. Lewis J. Kleinsmith. "Understanding Cancer and Related Topics: Understanding Angiogenesis." Rockville: National Cancer Institute, 2006. 14. P Boyle and B Levin (eds). "World Cancer Report 2008.", World Health Organization: International Agency for Research on Cancer. Lyon: 2008. 15. Martin, Lainie and Russell Schilder. "Novel Approaches in Advancing the Treatment of Epithelial Ovarian Cancer: The Role of Angiogenesis Inhibition" J Clin Oncol. 25, 2894-2901 (2007). 16. Spannuth, W. A. et al. "Angiogenesis as a Strategic Target for Ovarian Cancer Therapy." Nature. 5, No.4. (2008). 17. Kumaran, G. C. et al. "Minireview: Antiangiogenic Drugs in Ovarian Cancer." British J of Canc. 100, 1-7 (2009). 18. American Cancer Society. "Cancer Facts and Figures 2008." Atlanta: 2008. 19. American Cancer Society. "Ovarian Cancer Detailed Guide." Atlanta: 2008. Boehringer IngelheimPages: 1 [2]